NEW YORK (GenomeWeb News) – PerkinElmer reported after the close of the market Thursday that its fourth quarter revenues increased 4 percent year over year driven by gains for its Human Health segment.

The firm reported total revenues of $593.3 million for the three months ended Dec. 29, compared to $572.9 million for the fourth quarter of 2012. It beat analysts' consensus estimate of $589.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.